2 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 6 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 2, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Withdrawn 1 |
Follow Hematoma: new trials by email Literature Review of Hematoma trials Research Report on Hematoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intra-Arterial Bevacizumab as an Adjunct to Middle Meningeal Artery Embolization for Chronic Subdural Hematoma Bevacizumab (intra-arterial) - Chronic Subdural Hematoma | Phase 1 | Not yet recruiting | Dheeraj Gandhi | 18 | 2027-01-01 | 2026-07-27 |
| Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection Bevacizumab 2 mg/kg, Bevacizumab 4 mg/kg - Chronic Subdural Hematoma | Phase 1 | Completed | The Cooper Health System | 10 | 2024-06-17 | 2026-10-02 |
| A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) CM355 - Hematoma | Phase 1 / Phase 2 | Active not recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 184 | 2021-11-16 | 2022-01-27 |
| Efficacy of Bromocriptine For Fever Reduction in Acute Neurologic Injury Bromocriptine 5 MG, Acetaminophen 650 MG - Subarachnoid Hemorrhage, Subdural Hematoma | Phase 1 / Phase 2 | Completed | University of California, San Francisco | 47 | 2018-11-30 | 2021-06-24 |
| Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage PF-05230907 - Intracerebral Hemorrhage | Phase 1 | Terminated | Pfizer | 21 | 2016-11-01 | 2019-04-17 |
| Hypernatremia for the Prevention and Treatment of Cerebral Edema in Traumatic Brain Injury Induced, sustained hypernatremia using hypertonic saline, Standard of care (hypertonic saline and mannitol; serum sodium) - Traumatic Brain Injury, Subdural Hematoma | Phase 1 / Phase 2 | Withdrawn | Massachusetts General Hospital | 2012-07-01 | 2016-12-12 |
Brain Injuries, Traumatic (2) · Cerebral Hemorrhage (2) · Hematoma, Subdural (2) · Hematoma, Subdural, Chronic (2) · Brain Contusion (1) · Brain Diseases (1) · Brain Edema (1) · Brain Injuries (1) · Central Nervous System Diseases (1) · Craniocerebral Trauma (1) · Fever (1) · Head Injuries, Closed (1) · Hemorrhage (1) · Hypernatremia (1)
Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Cardiovascular Diseases (5) · Cerebrovascular Disorders (5) · Hemorrhage (5) · Vascular Diseases (5) · Brain Diseases (4) · Central Nervous System Diseases (4) · Intracranial Hemorrhage, Traumatic (4) · Intracranial Hemorrhages (4) · Nervous System Diseases (4) · Trauma, Nervous System (4) · Craniocerebral Trauma (3) · Wounds and Injuries (3)
Bevacizumab (2) · Acetaminophen (1) · Bromocriptine (1) · Infusions, Intra-Arterial (1) · Mannitol (1) · PF-05230907 (1) · Saline Solution, Hypertonic (1) · Standard of Care (1)
Beijing InnoCare Pharma Tech Co., Ltd. (1) · Dheeraj Gandhi (1) · Massachusetts General Hospital (1) · Pfizer (1) · The Cooper Health System (1) · University of California, San Francisco (1)
United States (3) · Canada (1) · China (1) · Spain (1) · United Kingdom (1)
Ajith J Thomas, MD (1) · Brian P Walcott, MD (1) · Brian V Nahed, MD (1) · Jane Khalife, MD (1) · Judy H Ch'ang, MD (1) · Manisha Koneru, MD (1) · Sameer A Sheth, MD PhD (1) · Yuqin Song, M.D. (1)
2015 (1)